Related Experiment Video
Updated: Feb 17, 2026
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
Trajectory of treatment decision-making willingness to behavior conversion level in lymphoma patients: a growth
Weiying Zhong1, Yongqin Ge1, Fangchen Gu1
1Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Purposes:
Treatment decision-making willingness and the actual degree of participation in treatment decisions in lymphoma patients are crucial factors influencing clinical outcomes and are closely related to disease prognosis. This study aimed to identify trajectories of treatment decision-making willingness to behavior conversion (TDMWTBC) level among lymphoma patients.
Methods:
A total of 278 lymphoma patients hospitalized in the hematology department of the First Affiliated Hospital of Soochow University were selected as the study population. Longitudinal surveys were conducted at four time points (time of diagnosis, second treatment cycle, mid-treatment evaluation, and end-of-treatment evaluation) using the Patient Willingness/Actual Participation in Treatment Decision-Making Questionnaire and the Family APGAR Index Questionnaire. Growth Mixture Model analysis was used to identify TDMWTBC trajectories, and their predictors were analysed using multinomial logistic regression.
Results:
Three distinct TDMWTBC trajectories were identified: the "Low Conversion Level - Fluctuating Group" (45.58%), the "Moderate Conversion Level - Continuously Rising Group" (30.53%), and the "High Conversion Level - Gradually Declining Group" (23.89%). Univariate analysis indicated that age, gender, educational level, place of residence, comorbidities, and family care level (P < 0.05) were associated with trajectory classes. Multinomial logistic regression further demonstrated that gender, place of residence, educational level, and family care level were predictors of different TDMWTBC trajectories.
Conclusions:
Lymphoma patients exhibit three distinct TDMWTBC trajectories. Relevant predictive indicators can forecast future TDMWTBC levels. It is necessary to screen patients and develop targeted interventions for those with different trajectories at specific stages.
